Why the study?
What is the incidence of late abnormal systolic cardiac function in long-term survivors of pediatric malignancies treated with anthracyclines?
Population
201 long-term survivors of pediatric malignancies who received chemotherapy including anthracyclines…
Design
Cohort
Follow-up
4 to 20 years (median, 7 years)
Authors
Loading...
Supports long-term surveillance in anthracycline-exposed survivors; leaves open optimal intervals and risk-based interventions.
What is the incidence of late abnormal systolic cardiac function in long-term survivors of pediatric malignancies treated with anthracyclines?
Long-term survivors of pediatric malignancies treated with anthracyclines have a 23% incidence of late cardiac abnormalities, highlighting the need for continued long-term echocardiographic surveillance.
Laurel J. Steinherz (1991) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: